<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34040085</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>26</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Oxaloacetate treatment preserves motor function in SOD1<sup>G93A</sup> mice and normalizes select neuroinflammation-related parameters in the spinal cord.</ArticleTitle><Pagination><StartPage>11051</StartPage><MedlinePgn>11051</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11051</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-90438-6</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) remains a devastating motor neuron disease with limited treatment options. Oxaloacetate treatment has a neuroprotective effect in rodent models of seizure and neurodegeneration. Therefore, we treated the ALS model superoxide dismutase 1 (SOD1) <sup>G93A</sup> mice with oxaloacetate and evaluated their neuromuscular function and lifespan. Treatment with oxaloacetate beginning in the presymptomatic stage significantly improved neuromuscular strength measured during the symptomatic stage in the injected mice compared to the non-treated group. Oxaloacetate treatment starting in the symptomatic stage significantly delayed limb paralysis compared with the non-treated group. For lifespan analysis, oxaloacetate treatment did not show a statistically significant positive effect, but the treatment did not shorten the lifespan. Mechanistically, SOD1<sup>G93A</sup> mice showed increased levels of tumor necrosis factor-&#x3b1; (TNF&#x3b1;) and peroxisome proliferative activated receptor gamma coactivator 1&#x3b1; (PGC-1&#x3b1;) mRNAs in the spinal cord. However, oxaloacetate treatment reverted these abnormal levels to that of wild-type mice. Similarly, the altered expression level of total NF-&#x3ba;B protein returned to that of wild-type mice with oxaloacetate treatment. These results suggest that the beneficial effects of oxaloacetate treatment in SOD1<sup>G93A</sup> mice may reflect the effects on neuroinflammation or bioenergetic stress.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tungtur</LastName><ForeName>Sudheer K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cardiovascular Division, University of Minnesota School of Medicine, Minneapolis, MN, 55455, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wilkins</LastName><ForeName>Heather M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Curriculum and Integrative Learning, Kansas City University, Joplin, MO, 64804, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badawi</LastName><ForeName>Yomna</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, 15260, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sage</LastName><ForeName>Jessica M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Basic Sciences, Kansas City University, Kansas City, MO, 64106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agbas</LastName><ForeName>Abdulbaki</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic Sciences, Kansas City University, Kansas City, MO, 64106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jawdat</LastName><ForeName>Omar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barohn</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Missouri-Columbia, Columbia, MO, 65212, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimune</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Cell Biology, School of Medicine, University of Kansas, Kansas City, KS, 66160, USA. nishimun@tmig.or.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Tokyo Metropolitan Institute of Gerontology, Neurobiology of Aging, 35-2 Sakaecho, Itabashi-ku, Tokyo, 173-0015, Japan. nishimun@tmig.or.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 RR016475</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG051470</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM103418</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 GM104936</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 HD090216</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078214</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG035982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071248">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C485290">Ppargc1a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>2F399MM81J</RegistryNumber><NameOfSubstance UI="D062907">Oxaloacetic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062907" MajorTopicYN="N">Oxaloacetic Acid</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071248" MajorTopicYN="N">Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34040085</ArticleId><ArticleId IdType="pmc">PMC8155202</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-90438-6</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-90438-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Edens BM, Miller N, Ma YC. Impaired autophagy and defective mitochondrial function: converging paths on the road to motor neuron degeneration. Front. Cell Neurosci. 2016;10:44. doi: 10.3389/fncel.2016.00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00044</ArticleId><ArticleId IdType="pmc">PMC4776126</ArticleId><ArticleId IdType="pubmed">26973461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Ann. Rev. Neurosci. 2010;33:409&#x2013;440. doi: 10.1146/annurev.neuro.051508.135722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.051508.135722</ArticleId><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 2011;7:603&#x2013;615. doi: 10.1038/nrneurol.2011.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.150</ArticleId><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle Nerve. 2006;33:598&#x2013;608. doi: 10.1002/mus.20489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20489</ArticleId><ArticleId IdType="pubmed">16372325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong PC, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14:1105&#x2013;1116. doi: 10.1016/0896-6273(95)90259-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90259-7</ArticleId><ArticleId IdType="pubmed">7605627</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH. Treating neurodegeneration by modifying mitochondria: potential solutions to a "complex" problem. Antioxid. Redox Signal. 2007;9:1591&#x2013;1603. doi: 10.1089/ars.2007.1676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.1676</ArticleId><ArticleId IdType="pubmed">17663643</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol. 2009;65(Suppl 1):S3&#x2013;9. doi: 10.1002/ana.21543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 1998;18:3241&#x2013;3250. doi: 10.1523/JNEUROSCI.18-09-03241.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.18-09-03241.1998</ArticleId><ArticleId IdType="pmc">PMC6792665</ArticleId><ArticleId IdType="pubmed">9547233</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, et al. ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import. Proc. Natl. Acad. Sci. 2010;107:21146&#x2013;21151. doi: 10.1073/pnas.1014862107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1014862107</ArticleId><ArticleId IdType="pmc">PMC3000256</ArticleId><ArticleId IdType="pubmed">21078990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffoli R, Bartalucci A, Frati A, Fornai F. Ultrastructural studies of ALS mitochondria connect altered function and permeability with defects of mitophagy and mitochondriogenesis. Front. Cell Neurosci. 2015;9:341. doi: 10.3389/fncel.2015.00341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00341</ArticleId><ArticleId IdType="pmc">PMC4555074</ArticleId><ArticleId IdType="pubmed">26388731</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano A, et al. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1984;43:471&#x2013;480. doi: 10.1097/00005072-198409000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-198409000-00002</ArticleId><ArticleId IdType="pubmed">6540800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hart MN, Cancilla PA, Frommes S, Hirano A. Anterior horn cell degeneration and Bunina-type inclusions associated with dementia. Acta Neuropathol. 1977;38:225&#x2013;228. doi: 10.1007/BF00688069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00688069</ArticleId><ArticleId IdType="pubmed">197771</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y, Hirayama K, Terao K. Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch. Neurol. 1987;44:103&#x2013;106. doi: 10.1001/archneur.1987.00520130079022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1987.00520130079022</ArticleId><ArticleId IdType="pubmed">3800708</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Parks JK, Pattee G, Parker WD., Jr Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor. Neuron. Disord. 2000;1:185&#x2013;190. doi: 10.1080/14660820050515179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820050515179</ArticleId><ArticleId IdType="pubmed">11464951</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers RS, et al. Impaired mitophagy plays a role in denervation of neuromuscular junctions in ALS mice. Front. Neurosci. 2017;11:473. doi: 10.3389/fnins.2017.00473.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00473</ArticleId><ArticleId IdType="pmc">PMC5575151</ArticleId><ArticleId IdType="pubmed">28890682</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. J. Neurochem. 2002;80:616&#x2013;625. doi: 10.1046/j.0022-3042.2001.00731.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0022-3042.2001.00731.x</ArticleId><ArticleId IdType="pubmed">11841569</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedemann FR, et al. Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 1998;156:65&#x2013;72. doi: 10.1016/S0022-510X(98)00008-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00008-2</ArticleId><ArticleId IdType="pubmed">9559989</ArticleId></ArticleIdList></Reference><Reference><Citation>Vielhaber S, et al. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain. 2000;123(Pt 7):1339&#x2013;1348. doi: 10.1093/brain/123.7.1339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/123.7.1339</ArticleId><ArticleId IdType="pubmed">10869047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzo F, Mirra A, Carri MT. Oxidative stress and mitochondrial damage in the pathogenesis of ALS: New perspectives. Neurosci Lett. 2006;1:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27150074</ArticleId></ArticleIdList></Reference><Reference><Citation>Browne EC, Abbott BM. Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting. Eur. J. Med. Chem. 2016;121:918&#x2013;925. doi: 10.1016/j.ejmech.2016.02.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.02.048</ArticleId><ArticleId IdType="pubmed">27012524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolf R, Khan MM, Wild F, Hashemolhosseini S. The impact of autophagy on peripheral synapses in health and disease. Front. Biosci. 2016;21:1474&#x2013;1487. doi: 10.2741/4467.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4467</ArticleId><ArticleId IdType="pubmed">27100517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins HM, et al. Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum. Mol. Genet. 2014;23:6528&#x2013;6541. doi: 10.1093/hmg/ddu371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu371</ArticleId><ArticleId IdType="pmc">PMC4271074</ArticleId><ArticleId IdType="pubmed">25027327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto HA, Mohanan PV. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol. Lett. 2003;143:115&#x2013;122. doi: 10.1016/S0378-4274(03)00114-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0378-4274(03)00114-0</ArticleId><ArticleId IdType="pubmed">12749815</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DS, Cash A, Hamadani L, Diemer T. Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway. Aging Cell. 2009;8:765&#x2013;768. doi: 10.1111/j.1474-9726.2009.00527.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2009.00527.x</ArticleId><ArticleId IdType="pmc">PMC2988682</ArticleId><ArticleId IdType="pubmed">19793063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruban A, et al. Combined treatment of an amyotrophic lateral sclerosis rat model with recombinant GOT1 and oxaloacetic acid: a novel neuroprotective treatment. Neurodegener. Dis. 2015;15:233&#x2013;242. doi: 10.1159/000382034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000382034</ArticleId><ArticleId IdType="pubmed">26113413</ArticleId></ArticleIdList></Reference><Reference><Citation>Wooley CM, et al. Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve. 2005;32:43&#x2013;50. doi: 10.1002/mus.20228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20228</ArticleId><ArticleId IdType="pmc">PMC1350398</ArticleId><ArticleId IdType="pubmed">15880561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayworth CR, Gonzalez-Lima F. Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model. Neuroscience. 2009;164:975&#x2013;985. doi: 10.1016/j.neuroscience.2009.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.08.031</ArticleId><ArticleId IdType="pmc">PMC2783710</ArticleId><ArticleId IdType="pubmed">19699279</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, et al. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiman-Patterson TD, et al. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 2005;236:1&#x2013;7. doi: 10.1016/j.jns.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2005.02.006</ArticleId><ArticleId IdType="pubmed">16024047</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner, M., Menzies, S. &amp; Lutz, C. Working with ALS mice, guidelines for preclinical testing &amp; colony management. PRIZE4LIFE, The Jackson Laboratory, 1&#x2013;28 (2009).</Citation></Reference><Reference><Citation>Ludolph AC, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008;9:4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Brohawn, D. G., O'Brien, L. C. &amp; Bennett, J. P., Jr. RNAseq Analyses Identify Tumor Necrosis Factor-Mediated Inflammation as a Major Abnormality in ALS Spinal Cord. PLoS One11, e0160520 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4972368</ArticleId><ArticleId IdType="pubmed">27487029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gowing G, Dequen F, Soucy G, Julien JP. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J. Neurosci. 2006;26:11397&#x2013;11402. doi: 10.1523/JNEUROSCI.0602-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0602-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674545</ArticleId><ArticleId IdType="pubmed">17079668</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruddle NH. Lymphotoxin and TNF: how it all began-a tribute to the travelers. Cytokine Growth Factor Rev. 2014;25:83&#x2013;89. doi: 10.1016/j.cytogfr.2014.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.02.001</ArticleId><ArticleId IdType="pmc">PMC4027955</ArticleId><ArticleId IdType="pubmed">24636534</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Xu S, Qian Y, Xiao Q. Resveratrol regulates microglia M1/M2 polarization via PGC-1alpha in conditions of neuroinflammatory injury. Brain Behav. Immun. 2017;64:162&#x2013;172. doi: 10.1016/j.bbi.2017.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2017.03.003</ArticleId><ArticleId IdType="pubmed">28268115</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. PPARgamma coactivator-1alpha (PGC-1alpha) protects neuroblastoma cells against amyloid-beta (Abeta) induced cell death and neuroinflammation via NF-kappaB pathway. BMC Neurosci. 2017;18:69. doi: 10.1186/s12868-017-0387-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-017-0387-7</ArticleId><ArticleId IdType="pmc">PMC5612334</ArticleId><ArticleId IdType="pubmed">28946859</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, et al. Microglia induce motor neuron death via the classical NF-kappaB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 1997;152(Suppl 1):S67&#x2013;73. doi: 10.1016/S0022-510X(97)00247-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(97)00247-5</ArticleId><ArticleId IdType="pubmed">9419057</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:639&#x2013;649. doi: 10.1038/nrneurol.2011.153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(3):707&#x2013;719. doi: 10.1093/brain/118.3.707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/118.3.707</ArticleId><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Contet C, Rawlins JN, Deacon RM. A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav Brain Res. 2001;124:33&#x2013;46. doi: 10.1016/S0166-4328(01)00231-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-4328(01)00231-5</ArticleId><ArticleId IdType="pubmed">11423164</ArticleId></ArticleIdList></Reference><Reference><Citation>Cossins J, et al. A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. Hum. Mol. Genet. 2004;13:2947&#x2013;2957. doi: 10.1093/hmg/ddh320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh320</ArticleId><ArticleId IdType="pubmed">15471888</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>